Dollar change -0.15
Percentage change -4.76	%

Peers: FATE ADAP KPTI PGEN ARGX TGTX BPMC MRNA VRTX

| Held by: IWM VTI VXF IWO VTWO IWN IWC SBIO RSSL VTWG

Index	RUT	P/E	-	EPS (ttm)	-0.40	Insider Own	36.40%	Shs Outstand	138.28M	Perf Week	11.11%
Market Cap	414.85M	Forward P/E	-	EPS next Y	-0.56	Insider Trans	-12.35%	Shs Float	87.95M	Perf Month	36.99%
Enterprise Value	308.59M	PEG	-	EPS next Q	-0.12	Inst Own	43.15%	Short Float	8.41%	Perf Quarter	76.47%
Income	-55.22M	P/S	488.06	EPS this Y	-39.17%	Inst Trans	0.42%	Short Ratio	8.77	Perf Half Y	21.46%
Sales	0.85M	P/B	3.76	EPS next Y	-10.78%	ROA	-37.74%	Short Interest	7.39M	Perf YTD	106.90%
Book/sh	0.80	P/C	3.68	EPS next 5Y	8.37%	ROE	-41.31%	52W High	4.08 -26.47%	Perf Year	185.71%
Cash/sh	0.81	P/FCF	-	EPS past 3/5Y	23.88% -104.70%	ROIC	-47.38%	52W Low	0.87 243.21%	Perf 3Y	9.49%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-94.59%	Volatility	8.33% 7.45%	Perf 5Y	-
Dividend TTM	-	EV/Sales	363.05	EPS Y/Y TTM	-14.07%	Oper. Margin	-7272.82%	ATR (14)	0.19	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.33	Sales Y/Y TTM	-	Profit Margin	-6496.35%	RSI (14)	63.31	Recom	1.10
Dividend Gr. 3/5Y	- -	Current Ratio	8.33	EPS Q/Q	-52.28%	SMA20	9.59%	Beta	1.29	Target Price	12.80
Payout	-	Debt/Eq	0.06	Sales Q/Q	-	SMA50	25.29%	Rel Volume	0.79	Prev Close	3.15
Employees	35	LT Debt/Eq	0.06	Earnings	May 08 BMO	SMA200	38.81%	Avg Volume	842.85K	Price	3.00
IPO	Apr 05, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.09% -	Trades		Volume	662,402	Change	-4.76%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-01-25	Resumed	Raymond James	Outperform	$9
Apr-02-25	Upgrade	Leerink Partners	Market Perform → Outperform	$6
Feb-24-25	Initiated	Guggenheim	Buy	$12
Feb-19-25	Initiated	Piper Sandler	Overweight	$12
Dec-23-24	Initiated	D. Boral Capital	Buy	$32
Nov-15-24	Downgrade	Leerink Partners	Outperform → Market Perform	$5 → $4
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy	$5
Jan-31-23	Initiated	Jefferies	Buy	$8
Jan-27-23	Initiated	Stifel	Buy	$9
May-23-22	Resumed	H.C. Wainwright	Buy	$12
Mar-15-22	Initiated	Ladenburg Thalmann	Buy	$7
Jan-19-22	Initiated	B. Riley Securities	Buy	$10
Dec-22-21	Initiated	Raymond James	Outperform	$5
Dec-20-21	Initiated	SVB Leerink	Outperform	$12
Dec-15-21	Initiated	Wedbush	Outperform	$8

Show Previous Ratings

May-28-25 08:00AM	Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-08-25 08:00AM	Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
May-06-25 08:00AM	Compass Therapeutics to Participate in Upcoming May Investor Events (GlobeNewswire) -9.14%
Apr-28-25 08:00AM	Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Apr-21-25 08:00AM	Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer (GlobeNewswire)
04:05PM	Loading…
Apr-02-25 04:05PM	Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum (GlobeNewswire) -24.55% -5.03%
Apr-01-25 07:00AM	Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer (GlobeNewswire) +17.89%
Mar-31-25 04:05PM	Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer (GlobeNewswire)
Mar-27-25 10:20AM	Is Compass Therapeutics (CMPX) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-02-25 10:22AM	Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-27-25 08:00AM	Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-29-25 08:00AM	Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-08-25 08:00AM	Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate (GlobeNewswire) +30.07%
Dec-10-24 08:00AM	Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer (GlobeNewswire) +7.88%
Dec-02-24 08:00AM	Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
08:30AM	Loading…
Nov-13-24 08:30AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire) -5.59%
Nov-12-24 08:00AM	Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire) -5.79%
Nov-08-24 10:05AM	Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Oct-04-24 10:31AM	Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-03-24 08:00AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Aug-12-24 08:00AM	Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-24 08:00AM	Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference (GlobeNewswire) -6.52%
Aug-06-24 08:00AM	Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer (GlobeNewswire)
Jul-10-24 12:00PM	Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's Why (Zacks) +9.94%
May-30-24 08:00AM	Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -7.48%
May-28-24 04:10PM	Compass Therapeutics Announces CEO Transition (GlobeNewswire)
May-23-24 05:05PM	Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 (GlobeNewswire)
May-14-24 08:00AM	Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
May-13-24 02:53PM	CMPX Stock Earnings: Compass Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Loading…
Apr-25-24 08:00AM	Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated (GlobeNewswire)
Apr-16-24 08:00AM	Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors (GlobeNewswire)
Apr-12-24 08:00AM	Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference (GlobeNewswire)
Apr-10-24 08:00AM	Compass Therapeutics to Participate in the Stifel Targeted Oncology Days (GlobeNewswire)
Apr-09-24 12:00PM	Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-21-24 10:54PM	CMPX Stock Earnings: Compass Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +5.66%
09:00AM	Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-29-24 08:00AM	Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-28-24 08:00AM	Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial (GlobeNewswire)
Feb-08-24 12:00PM	Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know (Zacks) +8.21%
Jan-05-24 08:00AM	Compass Therapeutics Provides Corporate Update (GlobeNewswire) +5.16%
Nov-09-23 08:17AM	Compass Therapeutics Inc (CMPX) Reports Q3 2023 Financial Results and Corporate Developments (GuruFocus.com) -6.40%
07:30AM	Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-23 08:00AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Aug-30-23 08:00AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Aug-03-23 08:00AM	Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-22-23 04:05PM	Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes (GlobeNewswire)
Jun-01-23 10:06AM	Compass Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
May-04-23 08:30AM	Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-26-23 08:30AM	Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ (GlobeNewswire)
Apr-19-23 08:30AM	Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days (GlobeNewswire) -5.00%
Mar-28-23 08:30AM	Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium (GlobeNewswire)
Mar-15-23 08:30AM	Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-16-23 07:28AM	Daily Vickers Top Buyers & Sellers for 02/16/2023 (Argus Research)
Feb-02-23 08:30AM	Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-25-23 06:39AM	Daily Vickers Top Buyers & Sellers for 01/25/2023 (Argus Research)
Jan-19-23 05:00PM	Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023 (GlobeNewswire) -10.93%
Jan-06-23 08:30AM	Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer (GlobeNewswire)
Dec-15-22 08:30AM	Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21 (GlobeNewswire)
Dec-01-22 08:30AM	Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab) (GlobeNewswire) +11.92%
Nov-22-22 08:00AM	Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-09-22 09:00AM	Compass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-08-22 08:00AM	Compass Therapeutics to Present at Upcoming Investment Conferences (GlobeNewswire) +10.10%
Nov-02-22 09:06AM	Compass Therapeutics Announces $80 Million Private Placement (GlobeNewswire) +10.53%
Oct-11-22 08:00AM	Compass Therapeutics Announces Clinical Collaboration with Merck to Evaluate CTX-471 in Combination with KEYTRUDA® (pembrolizumab) (GlobeNewswire) +8.80%
Sep-09-22 08:00AM	Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-02-22 08:00AM	Compass Therapeutics to Present at the 13th Annual Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Aug-01-22 08:00AM	Compass Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-18-22 07:05AM	Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position (GlobeNewswire)
May-31-22 08:00AM	Compass Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-22 08:00AM	Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference (GlobeNewswire) +6.56%
May-20-22 06:28AM	Trade Alert: The Co-Founder Of Compass Therapeutics, Inc. (NASDAQ:CMPX), Thomas Schuetz, Has Just Spent US$50k Buying A Few More Shares (Simply Wall St.) +6.65%
May-16-22 08:00AM	Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy (GlobeNewswire) +5.12%
May-09-22 01:59PM	Here's What Compass Therapeutics, Inc.'s (NASDAQ:CMPX) Shareholder Ownership Structure Looks Like (Simply Wall St.)
08:00AM	Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-05-22 08:00AM	Compass Therapeutics to Present at the Bank of America Securities 2022 Healthcare Conference on Thursday, May 12, 2022 at 11:20 a.m. PT (GlobeNewswire)
May-04-22 07:00AM	Compass Therapeutics Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers (GlobeNewswire)
May-03-22 04:01PM	Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009 (GlobeNewswire)
Apr-26-22 08:00AM	Compass Therapeutics Announces Appointment of Two New Directors to its Board (GlobeNewswire)
Apr-08-22 01:01PM	Compass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting (GlobeNewswire) -6.71%
Mar-30-22 08:00AM	Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans (GlobeNewswire) +5.56%
Mar-21-22 08:00AM	Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +6.15%
Feb-07-22 05:38PM	Monashee Investment Management LLC Buys Vanguard Total Stock Market ETF, Hyperfine Inc, Agree ... (GuruFocus.com) +9.39%
Jan-28-22 05:38PM	New Capital Management LP Buys Compass Therapeutics Inc, Sells Cambria Shareholder Yield ETF (GuruFocus.com) -6.42%
Jan-20-22 08:30AM	Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A) (GlobeNewswire) -5.30%
Jan-07-22 09:00AM	Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-22-21 10:00AM	Compass Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference (Business Wire)
Nov-12-21 08:30AM	Compass Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update (Business Wire)
Nov-03-21 08:04AM	Do Institutions Own Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares? (Simply Wall St.) -10.80%
Nov-01-21 11:13PM	Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market (Business Wire)
04:30PM	Compass Therapeutics Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market (Business Wire)
04:03PM	Compass Reports the Advancement of CTX-009, a Bispecific Antibody, to Phase 2a Development in Patients with Biliary Tract Cancers (BTC), and the Clearance of a Key Clinical Hurdle (Business Wire)
Oct-08-21 12:07PM	CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Business Wire)
Oct-01-21 07:00AM	Compass Therapeutics and ABL Bio Announce Presentation of CTX-009 Clinical Data as a Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Business Wire)
Sep-20-21 08:35AM	Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing (GlobeNewswire)
Sep-10-21 08:35AM	Life Sciences Virtual Investor Conference: Company Executives Present Live September 16th (GlobeNewswire)
Aug-13-21 07:00AM	Compass Therapeutics to Present at the Citi 16th Annual Biopharma Virtual Conference (Business Wire)
May-13-21 02:02PM	Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc. (Business Wire)

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schuetz Thomas J.	CHIEF EXECUTIVE OFFICER	May 27 '25	Buy	2.11	10,000	21,100	6,480,825	May 27 03:24 PM
GORDON CARL L	Director	Apr 09 '25	Sale	1.59	3,571,428	5,678,571	0	Apr 11 07:37 PM
ORBIMED ADVISORS LLC	Director	Apr 09 '25	Sale	1.59	3,571,428	5,678,571	0	Apr 11 07:24 PM
OrbiMed Genesis Master Fund, L	Director	Apr 09 '25	Proposed Sale	1.59	3,571,428	5,678,571		Apr 09 06:58 PM
The Biotech Growth Trust PLC	Director	Apr 09 '25	Proposed Sale	1.59	3,571,428	5,678,571		Apr 09 06:51 PM
Anderman Jonathan	Gen Counsel & Corporate Sec	Apr 07 '25	Buy	1.54	20,000	30,800	21,000	Apr 08 09:30 AM
Lerner Neil	CHIEF ACCOUNTING OFFICER	Apr 07 '25	Buy	1.42	20,000	28,400	320,000	Apr 08 09:25 AM

Open in Screener

MBX

MBX Biosciences Inc

Jul 18 • 04:00PM ET

11.75

Dollar change -0.44
Percentage change -3.65	%

Healthcare • Biotechnology • USA • NASD

MBX MBX Biosciences Inc daily Stock Chart

Held by: VTI IWM VXF IWN VTWO SCHA FESM IWC SBIO VTWV

Index	RUT	P/E	-	EPS (ttm)	-2.20	Insider Own	55.59%	Shs Outstand	33.42M	Perf Week	-9.89%
Market Cap	392.74M	Forward P/E	-	EPS next Y	-2.86	Insider Trans	2.42%	Shs Float	14.84M	Perf Month	16.34%
Enterprise Value	152.10M	PEG	-	EPS next Q	-0.75	Inst Own	54.40%	Short Float	33.49%	Perf Quarter	56.46%
Income	-73.47M	P/S	-	EPS this Y	51.98%	Inst Trans	21.67%	Short Ratio	16.19	Perf Half Y	-1.18%
Sales	0.00M	P/B	1.67	EPS next Y	-2.39%	ROA	-45.74%	Short Interest	4.97M	Perf YTD	-36.25%
Book/sh	7.04	P/C	1.63	EPS next 5Y	15.28%	ROE	-48.22%	52W High	27.50 -57.27%	Perf Year	-
Cash/sh	7.20	P/FCF	-	EPS past 3/5Y	-53.83% -	ROIC	-31.20%	52W Low	4.81 144.44%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.64% 11.04%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.23	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	23.31	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.62	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	23.31	EPS Q/Q	-93.37%	SMA20	-2.33%	Beta	-	Target Price	37.50
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-0.21%	Rel Volume	0.89	Prev Close	12.19
Employees	43	LT Debt/Eq	0.00	Earnings	May 12 BMO	SMA200	-16.69%	Avg Volume	306.94K	Price	11.75
IPO	Sep 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.79% -	Trades		Volume	273,419	Change	-3.65%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-16-25	Initiated	Oppenheimer	Outperform	$38
Apr-10-25	Initiated	Citizens JMP	Mkt Outperform	$38
Oct-08-24	Initiated	Stifel	Buy	$40
Oct-08-24	Initiated	JP Morgan	Overweight	$30
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$44

Jun-23-25 08:00AM	MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development (GlobeNewswire)
Jun-16-25 08:00AM	MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity (GlobeNewswire)
Jun-10-25 08:00AM	MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions (GlobeNewswire)
May-20-25 08:00AM	MBX Biosciences to Participate in June Investor Conferences (GlobeNewswire)
May-15-25 07:16AM	Microbix Reports Results for Q2 Fiscal 2025 (GlobeNewswire)
07:00AM	Loading…
May-13-25 07:00AM	Microbix & Aurevia Introduce Novel EQA Scheme (GlobeNewswire) -7.81%
May-12-25 08:00AM	MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-08-25 07:00AM	Microbix Schedules Release of Results for Q2 Fiscal 2025 (GlobeNewswire) +8.13%
May-05-25 07:00AM	Microbix's Clot-Buster Drug Project Advances (GlobeNewswire)
Apr-22-25 08:00AM	MBX Biosciences to Participate in Citizens and RBC May Investor Conferences (GlobeNewswire) +13.09%
Apr-07-25 08:00AM	MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors (GlobeNewswire)
Mar-26-25 08:00AM	MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-25 08:00AM	MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-05-25 08:00AM	MBX Biosciences Announces Additions to Leadership Team (GlobeNewswire)
Mar-03-25 08:00AM	MBX Biosciences Completes Enrollment in Phase 2 Avail Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism (GlobeNewswire) +5.62%
08:00AM	Loading…
Feb-18-25 08:00AM	MBX Biosciences to Participate in March Investor Conferences (GlobeNewswire)
Jan-23-25 08:00AM	MBX Biosciences to Participate in Upcoming February Investor Conferences (GlobeNewswire) +8.11%
Jan-07-25 11:47AM	MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action (Benzinga) -10.32%
07:00AM	MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia (GlobeNewswire)
Dec-18-24 08:00AM	MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-02-24 08:00AM	MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism (GlobeNewswire) -6.59%
Nov-18-24 08:00AM	MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia (GlobeNewswire) -6.76%
Nov-07-24 08:00AM	MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-24 08:00AM	MBX Biosciences to Participate in Upcoming November Investor Conferences (GlobeNewswire) -6.50%
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Sep-30-24 08:00AM	MBX Biosciences Presents MBX 2109 Phase 2 Avail Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting (GlobeNewswire) +8.48%
Sep-23-24 07:05PM	Deep Track Capital, LP's Strategic Acquisition in MBX Biosciences Inc (GuruFocus.com)
Sep-18-24 03:19AM	OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc (GuruFocus.com)
Sep-16-24 04:05PM	MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.46%
Sep-12-24 07:11PM	MBX Biosciences Announces Pricing of Initial Public Offering (GlobeNewswire)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pescovitz Ora H.	Director	Apr 08 '25	Buy	5.89	7,693	45,312	24,329	Apr 10 08:39 AM
GORDON CARL L	Director	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19 05:56 PM
GORDON CARL L	Director	Feb 14 '25	Buy	9.87	47,502	468,793	3,205,930	Feb 19 05:56 PM
ORBIMED ADVISORS LLC	Director	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19 05:52 PM
ORBIMED ADVISORS LLC	Director	Feb 14 '25	Buy	9.87	47,502	468,793	3,205,930	Feb 19 05:52 PM
Hawryluk P. Kent	President & CEO	Feb 04 '25	Buy	10.69	50,000	534,500	448,277	Feb 05 04:17 PM
Mathers Edward T	Director	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:28 PM
BASKETT FOREST	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:26 PM
Behbahani Ali	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:24 PM
Chang Carmen	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:23 PM
Florence Anthony A. Jr.	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:21 PM
Makhzoumi Mohamad	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:20 PM
Walker Paul Edward	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:18 PM
Yang Rick	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:17 PM
SANDELL SCOTT D	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:14 PM
ORBIMED ADVISORS LLC	Director	Sep 16 '24	Buy	16.00	750,000	12,000,000	3,158,428	Sep 17 08:13 PM
New Enterprise Associates 17,	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:12 PM
Frazier Life Sciences X, L.P.	10% Owner	Sep 16 '24	Buy	16.00	625,000	10,000,000	4,552,774	Sep 17 08:11 PM
Heron Patrick J	Director	Sep 16 '24	Buy	16.00	625,000	10,000,000	4,552,774	Sep 17 08:09 PM
Aynechi Tiba	Director	Sep 16 '24	Buy	16.00	750,000	12,000,000	2,136,335	Sep 17 08:05 PM
GORDON CARL L	Director	Sep 16 '24	Buy	16.00	750,000	12,000,000	3,158,428	Sep 17 08:05 PM

Open in Screener

KROS

Keros Therapeutics Inc

Jul 18 • 04:00PM ET

13.75

Dollar change -0.61
Percentage change -4.25	%

Healthcare • Biotechnology • USA • NASD

KROS Keros Therapeutics Inc daily Stock Chart

Peers: SRPT VRTX ALNY IONS ARWR TVRD BLUE RGNX MCRB PBYI

| Held by: VTI IWM XBI VXF JSMD IWN IBB SCHA VTWO JSML

Index	RUT	P/E	-	EPS (ttm)	-0.18	Insider Own	17.24%	Shs Outstand	40.56M	Perf Week	-4.78%
Market Cap	558.46M	Forward P/E	-	EPS next Y	-4.23	Insider Trans	15.40%	Shs Float	33.61M	Perf Month	2.15%
Enterprise Value	-143.67M	PEG	-	EPS next Q	-1.13	Inst Own	89.04%	Short Float	15.37%	Perf Quarter	1.63%
Income	4.21M	P/S	2.60	EPS this Y	105.64%	Inst Trans	-11.47%	Short Ratio	7.52	Perf Half Y	31.96%
Sales	214.71M	P/B	0.77	EPS next Y	-1598.47%	ROA	0.66%	Short Interest	5.16M	Perf YTD	-13.14%
Book/sh	17.97	P/C	0.78	EPS next 5Y	3.04%	ROE	0.71%	52W High	72.37 -81.00%	Perf Year	-73.64%
Cash/sh	17.74	P/FCF	12.89	EPS past 3/5Y	-25.74% -48.13%	ROIC	0.57%	52W Low	9.12 50.77%	Perf 3Y	-54.01%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-43.89% -18.71%	Gross Margin	99.40%	Volatility	3.69% 3.14%	Perf 5Y	-55.36%
Dividend TTM	-	EV/Sales	-0.67	EPS Y/Y TTM	97.21%	Oper. Margin	-4.80%	ATR (14)	0.49	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	19.29	Sales Y/Y TTM	91657.69%	Profit Margin	1.96%	RSI (14)	45.94	Recom	1.83
Dividend Gr. 3/5Y	- -	Current Ratio	19.29	EPS Q/Q	399.53%	SMA20	-0.77%	Beta	1.33	Target Price	24.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	254413.25%	SMA50	-1.74%	Rel Volume	0.67	Prev Close	14.36
Employees	169	LT Debt/Eq	0.02	Earnings	May 06 AMC	SMA200	-46.08%	Avg Volume	686.68K	Price	13.75
IPO	Apr 08, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	413.83% 11188.13%	Trades		Volume	458,344	Change	-4.25%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-10-25	Downgrade	BofA Securities	Buy → Neutral	$18
Jan-21-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-17-25	Downgrade	Wedbush	Outperform → Neutral	$15
Dec-16-24	Reiterated	Oppenheimer	Outperform	$102 → $63
Dec-16-24	Downgrade	Guggenheim	Buy → Neutral
Dec-13-24	Reiterated	H.C. Wainwright	Buy	$100 → $47
Dec-12-24	Downgrade	William Blair	Outperform → Mkt Perform
Dec-12-24	Downgrade	TD Cowen	Buy → Hold
Dec-12-24	Downgrade	BTIG Research	Buy → Neutral
Nov-05-24	Initiated	Jefferies	Buy
Oct-24-24	Initiated	Cantor Fitzgerald	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-23-24	Initiated	Guggenheim	Buy	$96
Jun-25-24	Initiated	Oppenheimer	Outperform	$102
Feb-21-24	Initiated	William Blair	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight	$60
Jul-31-23	Initiated	Wedbush	Outperform	$86
Jul-26-23	Initiated	BofA Securities	Buy	$65
Feb-14-23	Initiated	Cowen	Outperform
Oct-18-22	Initiated	Truist	Buy	$100

Show Previous Ratings

Jul-18-25 11:28AM	RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure (Zacks)
10:39AM	FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo (Zacks)
Jul-17-25 08:00AM	Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept (GlobeNewswire)
Jul-10-25 12:10PM	KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up (Zacks)
11:09AM	RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data (Zacks)
09:40AM	Loading…
Jun-11-25 09:40AM	McDonalds downgraded on GLP-1 drug worries: Wall Streets top analyst calls (TipRanks)
Jun-10-25 02:37PM	Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst (Benzinga)
Jun-09-25 03:12PM	ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal (PR Newswire) -6.32%
06:55AM	Keros Announces Return of $375 Million in Excess Capital to Stockholders (GlobeNewswire)
Jun-06-25 04:01PM	Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-30-25 06:36AM	Keros lays off nearly half its staff; Astellas buys into a China biotechs ADC (BioPharma Dive)
May-29-25 11:24PM	Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial (Insider Monkey)
12:54PM	Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% (Benzinga)
06:55AM	Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring (GlobeNewswire)
May-27-25 01:45PM	Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Keros' Director Nominees (GlobeNewswire)
08:00AM	Loading…
May-21-25 08:00AM	ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth (PR Newswire)
May-19-25 08:00AM	Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value (GlobeNewswire)
May-12-25 12:11PM	ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth (PR Newswire)
08:00AM	Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference (GlobeNewswire)
May-08-25 05:31PM	Keros Reinforces Commitment to Maximizing Stockholder Value (GlobeNewswire)
02:10PM	ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders (PR Newswire)
May-06-25 07:10PM	Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates (Zacks) -5.46%
04:01PM	Keros Therapeutics Reports Recent First Quarter 2025 Financial Results (GlobeNewswire)
May-05-25 05:10PM	Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-02-25 08:40AM	Implied Volatility Surging for Keros Therapeutics Stock Options (Zacks)
Apr-11-25 02:13PM	Keros Therapeutics: Strategic Alternatives Could Bring About Value Creation (Seeking Alpha)
12:05PM	Prada to acquire Versace, CarMax reports mixed Q4 results: Morning Buzz (TipRanks)
11:57AM	KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5% (Zacks)
Apr-10-25 12:58PM	Keros Therapeutics considers sale amid investor pressure (Pharmaceutical Technology) +18.49%
06:00AM	Keros Therapeutics Announces Review of Strategic Alternatives (GlobeNewswire)
06:00AM	Loading…
Mar-31-25 06:00AM	Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers (GlobeNewswire) -5.56%
Mar-21-25 09:55AM	Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet (Zacks)
Mar-05-25 09:55AM	Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade (Zacks)
Feb-28-25 05:00PM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
Feb-26-25 05:10PM	Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Jan-30-25 08:00AM	Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-22-25 08:53AM	Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock? (Zacks)
Jan-21-25 08:00AM	Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept (GlobeNewswire) +5.06%
Jan-20-25 09:35AM	Down -36.23% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround (Zacks)
Jan-16-25 09:35AM	Here's Why Keros Therapeutics (KROS) is Poised for a Turnaround After Losing -39.17% in 4 Weeks (Zacks)
Jan-15-25 06:30AM	Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial (GlobeNewswire) -16.51%
Dec-14-24 06:50AM	Keros Therapeutics price target raised to $28 from $11 at Wells Fargo (TipRanks)
Dec-12-24 04:11PM	Keros Plummets 73% After Unexpected Side Effects 'Shock' Its Lead Drug (Investor's Business Daily) -73.15%
09:15AM	Keros Therapeutics Plummets 73% On Unexpected Side Effects In Hypertension Study (Investor's Business Daily)
06:02AM	Keros shares collapse on unanticipated setback for lung disease drug (BioPharma Dive)
06:00AM	Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial (GlobeNewswire)
Dec-09-24 07:30PM	Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Dec-04-24 04:31AM	Takeda licensed for anaemia therapy by Keros Therapeutics (Pharmaceutical Technology) +8.85%
Dec-03-24 12:37PM	Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst (Benzinga) +9.78%
07:00AM	Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics (Business Wire)
07:00AM	Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept (GlobeNewswire)
Nov-26-24 08:00AM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
Nov-06-24 04:01PM	Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results (GlobeNewswire) +6.18%
08:00AM	Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference (GlobeNewswire)
Nov-05-24 09:00AM	Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Oct-16-24 08:00AM	Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer (GlobeNewswire)
Sep-12-24 08:00AM	Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-05-24 03:24PM	Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark (Investor's Business Daily)
Sep-03-24 08:00AM	Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial (GlobeNewswire) +5.38%
Aug-28-24 08:00AM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
Aug-07-24 11:53PM	KROS Stock Earnings: Keros Therapeutics Misses EPS for Q2 2024 (InvestorPlace) -6.89%
04:01PM	Keros Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-17-24 04:01PM	Keros Therapeutics Announces Leadership Updates (GlobeNewswire) -9.68%
06:00AM	Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association (GlobeNewswire)
Jun-04-24 08:00AM	Keros Therapeutics to Host a Corporate Update Conference Call and Webcast (GlobeNewswire)
Jun-03-24 08:00AM	Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-28-24 04:01PM	Keros Therapeutics Appoints Jean-Jacques Bienaime to its Board of Directors (GlobeNewswire)
04:01PM	Keros Therapeutics Appoints Jean-Jacques Bienaim to its Board of Directors (GlobeNewswire)
May-14-24 10:00AM	Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association (GlobeNewswire)
May-10-24 01:25PM	Keros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical Trials (GuruFocus.com) -5.78%
May-08-24 12:54PM	KROS Stock Earnings: Keros Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results (GlobeNewswire)
Mar-14-24 08:00AM	Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes (GlobeNewswire)
Mar-05-24 08:00AM	Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference (GlobeNewswire)
Feb-28-24 04:42PM	Keros Therapeutics Inc (KROS) Reports Increased R&D Spending and Net Loss in 2023 (GuruFocus.com)
04:01PM	Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
08:50AM	Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Feb-21-24 09:55AM	Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect? (Zacks)
Feb-12-24 08:50AM	Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why (Zacks) +7.02%
Jan-31-24 09:55AM	Wall Street Analysts Predict a 45.35% Upside in Keros Therapeutics, Inc. (KROS): Here's What You Should Know (Zacks)
Jan-29-24 08:00AM	Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress (GlobeNewswire)
Jan-24-24 08:50AM	Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jan-23-24 09:55AM	Keros Therapeutics, Inc. (KROS) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Jan-15-24 09:55AM	How Much Upside is Left in Keros Therapeutics, Inc. (KROS)? Wall Street Analysts Think 57.46% (Zacks)
Jan-09-24 08:00AM	Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock (GlobeNewswire)
Jan-03-24 09:29PM	Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +18.47%
04:05PM	Keros Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
08:00AM	Keros Therapeutics to Develop KER-065 for the Treatment of Obesity (GlobeNewswire)
Dec-15-23 06:39PM	HollySys Automation, Keros Therapeutics, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-11-23 06:00AM	Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire) -20.53%
Nov-07-23 08:00AM	Keros Therapeutics to Present at Upcoming Healthcare Conferences (GlobeNewswire)
Nov-06-23 08:00AM	Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 09:00AM	Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Oct-04-23 08:00AM	Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society (GlobeNewswire)
Sep-05-23 08:00AM	Keros Therapeutics to Present at Upcoming Healthcare Conferences (GlobeNewswire)
Aug-07-23 08:00AM	Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-31-23 09:51AM	Adobe upgraded, Salesforce downgraded: Wall Street's top analyst calls (The Fly)
Jul-27-23 04:01PM	Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension (GlobeNewswire) -8.01% +6.90%
Jul-24-23 08:00AM	Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension (GlobeNewswire)

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ADAR1 Capital Management, LLC	10% Owner	Apr 09 '25	Buy	10.13	934,258	9,464,512	4,392,737	Apr 11 09:57 PM
Seehra Jasbir	CHIEF EXECUTIVE OFFICER	Apr 04 '25	Option Exercise	0.30	49,367	14,810	302,223	Apr 07 04:15 PM
GORDON CARL L	Director	Aug 13 '24	Sale	44.01	250,000	11,002,500	119,522	Aug 15 05:06 PM
ORBIMED ADVISORS LLC	Director	Aug 13 '24	Sale	44.01	250,000	11,002,500	119,522	Aug 15 05:01 PM
OrbiMed Genesis Master Fund, L	Shareholder	Aug 13 '24	Proposed Sale	44.84	29,400	1,318,296		Aug 13 04:12 PM
OrbiMed Private Investments VI	Shareholder	Aug 13 '24	Proposed Sale	44.84	220,600	9,891,704		Aug 13 04:09 PM

Dollar change +0.04
Percentage change 0.71	%

TERN Terns Pharmaceuticals Inc daily Stock Chart

Peers: MDGL VKTX AKRO MNOV LGND GLMD BCRX XBIT ACAD AMRN

| Held by: IWM VTI VXF IWN IBB VTWO OZEM DFAS DFAT IWC

Index	RUT	P/E	-	EPS (ttm)	-1.09	Insider Own	23.99%	Shs Outstand	87.30M	Perf Week	15.10%
Market Cap	492.59M	Forward P/E	-	EPS next Y	-1.21	Insider Trans	0.24%	Shs Float	66.38M	Perf Month	44.62%
Enterprise Value	159.57M	PEG	-	EPS next Q	-0.29	Inst Own	78.92%	Short Float	9.21%	Perf Quarter	151.79%
Income	-90.39M	P/S	-	EPS this Y	-4.94%	Inst Trans	-2.60%	Short Ratio	6.72	Perf Half Y	21.81%
Sales	0.00M	P/B	1.51	EPS next Y	-3.24%	ROA	-30.84%	Short Interest	6.12M	Perf YTD	1.81%
Book/sh	3.73	P/C	1.47	EPS next 5Y	-7.03%	ROE	-32.12%	52W High	11.40 -50.53%	Perf Year	-41.86%
Cash/sh	3.83	P/FCF	-	EPS past 3/5Y	17.43% 16.38%	ROIC	-27.65%	52W Low	1.87 202.41%	Perf 3Y	116.92%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.44% 7.68%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	13.56%	Oper. Margin	-	ATR (14)	0.31	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	30.89	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	77.28	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	30.89	EPS Q/Q	13.07%	SMA20	26.34%	Beta	-0.10	Target Price	20.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	48.92%	Rel Volume	1.23	Prev Close	5.60
Employees	59	LT Debt/Eq	0.00	Earnings	May 08 AMC	SMA200	19.67%	Avg Volume	909.34K	Price	5.64
IPO	Feb 05, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	11.53% -	Trades		Volume	1,114,978	Change	0.71%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-28-25	Initiated	William Blair	Mkt Perform
Oct-31-24	Initiated	Oppenheimer	Outperform	$82
Jun-22-23	Initiated	Mizuho	Buy	$16
Jun-07-23	Initiated	Jefferies	Buy	$18
May-31-23	Initiated	ROTH MKM	Buy	$23
May-08-23	Initiated	BMO Capital Markets	Outperform	$18
Feb-14-23	Initiated	JMP Securities	Mkt Outperform	$17
Feb-07-23	Initiated	UBS	Buy	$19
Sep-12-22	Initiated	H.C. Wainwright	Neutral	$6
Sep-14-21	Resumed	Goldman	Buy	$21
Mar-02-21	Initiated	JP Morgan	Overweight	$32
Mar-02-21	Initiated	Goldman	Buy	$29
Mar-02-21	Initiated	Cowen	Outperform

Show Previous Ratings

Jun-23-25 04:07PM	Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions (GlobeNewswire) -5.64%
May-29-25 04:05PM	Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-14-25 09:30AM	Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701 (GlobeNewswire)
May-09-25 07:54AM	Is Terns Pharmaceuticals, Inc. (TERN) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-08-25 04:05PM	Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
04:05PM	Loading…
May-02-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) -5.71%
Apr-30-25 04:05PM	Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference (GlobeNewswire) +6.11% +7.88%
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Apr-07-25 09:35AM	Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround (Zacks)
Apr-03-25 09:35AM	Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN) (Zacks) -6.43%
Apr-02-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Mar-26-25 12:00PM	All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy (Zacks) -6.63%
Mar-20-25 04:05PM	Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates (GlobeNewswire) +6.69%
Mar-09-25 10:03AM	This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street (Motley Fool)
Feb-26-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
08:05AM	Loading…
Feb-25-25 08:05AM	Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference (GlobeNewswire)
03:00AM	Its CEO died. The company scrapped a promising program. Now, for their 2nd act. (Pharma Voice)
Feb-24-25 04:05PM	Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer (GlobeNewswire) -6.87%
Feb-20-25 04:05PM	Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors (GlobeNewswire)
Feb-05-25 04:05PM	Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-03-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-08-25 04:05PM	Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.84%
Jan-02-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Dec-16-24 01:10PM	Is Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? (Insider Monkey)
Dec-03-24 07:00AM	Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia (GlobeNewswire)
Dec-02-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-18-24 04:05PM	Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors (GlobeNewswire) -7.62%
Nov-12-24 04:05PM	Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire) -5.44%
Nov-06-24 04:05PM	Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-07-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) -5.08%
03:22AM	Loading…
Sep-24-24 03:22AM	Insiders Snap Up These 2 Strong Buy Stocks (TipRanks)
Sep-18-24 10:07AM	This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments (Motley Fool) +6.02%
Sep-17-24 01:30AM	OrbiMed Advisors LLC Increases Stake in Terns Pharmaceuticals Inc (GuruFocus.com)
Sep-15-24 07:21AM	Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now. (Motley Fool)
06:09AM	Should You Invest in This Under-the-Radar Weight Loss Stock? (Motley Fool)
Sep-14-24 10:12AM	1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More (Motley Fool)
Sep-12-24 07:00PM	Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -10.96% -5.84%
Sep-10-24 10:50PM	Terns Announces Pricing of Upsized $150.15 Million Public Offering (GlobeNewswire) +23.14%
04:52AM	Terns Pharmaceuticals reports positive data from Phase I trial of obesity treatment (Clinical Trials Arena)
Sep-09-24 04:01PM	Terns Announces Proposed Public Offering (GlobeNewswire) +16.77%
09:58AM	Terns Pharmaceuticals Stock Is Soaring on Good Data for Weight-Loss Pill (Barrons.com)
09:24AM	Terns Pharmaceuticals' Oral GLP-1 Reaches Phase 1 Finish Line With Encouraging Weight Loss Data After One Month (Benzinga)
08:06AM	Early study data puts Terns among obesity drug contenders (BioPharma Dive)
07:05AM	Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity (GlobeNewswire)
Aug-28-24 09:55AM	Wall Street Analysts Think Terns Pharmaceuticals (TERN) Could Surge 78.74%: Read This Before Placing a Bet (Zacks)
Aug-05-24 09:56PM	TERN Stock Earnings: Terns Pharma Beats EPS for Q2 2024 (InvestorPlace)
04:05PM	Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Aug-02-24 01:54PM	3 Biotech Stocks That Could Have Investors Grinning Soon (InvestorPlace)
Aug-01-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jul-29-24 04:05PM	Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition (GlobeNewswire) -7.55% -7.92%
Jul-26-24 06:40PM	Burger King Parent Company and More Stocks See Action From Activist Investors (Barrons.com)
Jul-20-24 09:30AM	Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs? (Motley Fool)
Jun-21-24 06:30PM	Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA's 84th Annual Scientific Sessions and Upcoming Conference Participation (GlobeNewswire)
Jun-19-24 01:27PM	Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue? (Zacks)
Jun-04-24 09:55AM	Wall Street Analysts Believe Terns Pharmaceuticals (TERN) Could Rally 136.44%: Here's is How to Trade (Zacks)
Jun-03-24 04:10PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
May-30-24 08:05AM	Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-17-24 04:05PM	Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day (GlobeNewswire) +5.93%
May-13-24 01:53PM	TERN Stock Earnings: Terns Pharma Beats EPS for Q1 2024 (InvestorPlace) +5.94%
09:32AM	Terns Pharmaceuticals Inc (TERN) Q1 2024 Earnings: Misses Analyst Net Loss Projections (GuruFocus.com)
08:05AM	Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
May-08-24 04:05PM	Terns Pharmaceuticals Announces Leadership Changes (GlobeNewswire) +5.03%
May-07-24 04:05PM	Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024 (GlobeNewswire)
May-03-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.43%
Apr-29-24 04:05PM	Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation (GlobeNewswire)
Apr-10-24 04:05PM	Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer (GlobeNewswire) -5.23%
Mar-14-24 04:05PM	Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates (GlobeNewswire) -5.23% +7.30%
Mar-11-24 04:05PM	Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia (GlobeNewswire) -8.38%
Mar-07-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Feb-27-24 04:05PM	Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences (GlobeNewswire) +5.69% -6.26%
Feb-07-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.13% +9.81%
08:05AM	Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer (GlobeNewswire)
Feb-02-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-04-24 04:05PM	Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.52%
Jan-03-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-29-23 04:05PM	Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit (GlobeNewswire) +6.97%
Nov-27-23 04:05PM	Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer (GlobeNewswire) +5.96%
Nov-14-23 12:16PM	Terns Pharmaceuticals Inc (TERN) Reports Q3 2023 Financials and Corporate Progress (GuruFocus.com) +5.34%
08:05AM	Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
Nov-13-23 08:05AM	Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR- Agonist TERN-501 in NASH at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-09-23 08:05AM	Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences (GlobeNewswire) -21.89%
Nov-03-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-02-23 04:05PM	Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity (GlobeNewswire) -8.00%
Oct-19-23 04:05PM	Terns Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.61%
Oct-16-23 08:05AM	Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia (GlobeNewswire)
Oct-03-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Sep-06-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Sep-05-23 04:05PM	Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-08-23 04:15PM	Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire) -13.73%
04:05PM	Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR- Agonist TERN-501 in NASH (GlobeNewswire)
Aug-03-23 06:00PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) -6.80%
05:05PM	Terns Pharmaceuticals Announces Leadership Transition (GlobeNewswire)
Jul-28-23 07:01PM	Deep Track Capital, LP Enters Position in Terns Pharmaceuticals Inc (GuruFocus.com)
Jul-18-23 04:05PM	Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia (GlobeNewswire) +5.17%
Jul-05-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jun-26-23 04:05PM	Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADAs 83rd Annual Scientific Session and Upcoming Events (GlobeNewswire) -12.16% -23.52%
Jun-06-23 04:30PM	Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
Jun-02-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +5.17%
May-28-23 09:45AM	Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth (Simply Wall St.)
May-25-23 05:05PM	Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting (GlobeNewswire)

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kuriakose Emil	Chief Medical Officer	Jul 01 '25	Sale	4.27	853	3,640	52,464	Jul 03 02:55 PM
Gengos Andrew	Chief Financial Officer	Jun 27 '25	Buy	3.93	10,000	39,283	25,000	Jun 30 05:38 PM
Burroughs Amy L.	Chief Executive Officer	Jun 25 '25	Buy	3.87	23,314	90,230	47,083	Jun 25 06:08 PM
Gengos Andrew	Chief Financial Officer	Jun 13 '25	Buy	3.73	10,000	37,350	10,000	Jun 16 06:05 PM
Gengos Andrew	Chief Financial Officer	Jun 16 '25	Buy	3.95	5,000	19,732	15,000	Jun 16 06:05 PM
Kuriakose Emil	Chief Medical Officer	Apr 01 '25	Sale	2.49	952	2,366	53,317	Apr 02 06:48 PM
Jung Melita Sun	Chief Business Officer	Nov 30 '24	Buy	5.11	2,250	11,498	2,250	Feb 03 07:28 PM
Burroughs Amy L.	Chief Executive Officer	Nov 30 '24	Buy	5.11	510	2,606	19,609	Feb 03 07:25 PM
Kuriakose Emil	Chief Medical Officer	Jan 02 '25	Sale	5.71	4,481	25,607	54,269	Jan 06 07:30 PM
Vignola Mark J.	Chief Financial Officer	Jan 06 '25	Sale	5.80	9,059	52,500	74,752	Jan 06 07:30 PM
Vignola Mark J.	Chief Financial Officer	Jan 02 '25	Sale	5.72	8,129	46,524	83,811	Jan 06 07:30 PM
Quigley Jill M.	Director	Jan 06 '25	Sale	5.79	8,760	50,758	0	Jan 06 07:30 PM
Quigley Jill M.	Director	Jan 02 '25	Sale	5.72	6,240	35,702	8,760	Jan 06 07:30 PM
MARK J VIGNOLA	Officer	Jan 06 '25	Proposed Sale	5.75	9,059	52,089		Jan 06 04:29 PM
JILL QUIGLEY	Director	Jan 06 '25	Proposed Sale	5.75	8,760	50,370		Jan 06 04:29 PM
Burroughs Amy L.	Chief Executive Officer	Dec 05 '24	Buy	7.15	15,450	110,468	19,099	Dec 09 06:04 PM
Lu Hongbo	Director	Sep 12 '24	Buy	10.50	476,190	4,999,995	476,190	Sep 17 07:48 PM
Vignola Mark J.	Chief Financial Officer	Sep 10 '24	Option Exercise	5.36	10,000	53,600	101,940	Sep 12 06:10 PM
Vignola Mark J.	Chief Financial Officer	Sep 10 '24	Sale	11.00	10,000	110,000	91,940	Sep 12 06:10 PM
Quigley Jill M.	Director	Sep 09 '24	Option Exercise	1.82	17,235	31,368	32,235	Sep 11 06:00 PM
Quigley Jill M.	Director	Sep 09 '24	Sale	10.00	17,235	172,350	15,000	Sep 11 06:00 PM
SEOKHO BRYAN YOON	Officer	Sep 10 '24	Proposed Sale	9.12	10,000	91,200		Sep 10 04:21 PM
MARK J VIGNOLA	Officer	Sep 10 '24	Proposed Sale	9.12	10,000	91,200		Sep 10 04:21 PM
JILL QUIGLEY	Officer	Sep 09 '24	Proposed Sale	7.81	8,857	69,173		Sep 09 04:30 PM
Quigley Jill M.	Director	Aug 02 '24	Sale	7.50	8,857	66,432	15,000	Aug 05 08:11 PM
Quigley Jill M.	Director	Aug 01 '24	Sale	7.68	6,143	47,148	23,857	Aug 05 08:11 PM

Open in Screener

AVBP

ArriVent BioPharma Inc

Jul 18 • 04:00PM ET

22.05

Dollar change -0.67
Percentage change -2.95	%

Healthcare • Biotechnology • USA • NASD

AVBP ArriVent BioPharma Inc daily Stock Chart

Peers: AMGN SRPT VRTX REGN MRNA BIIB GILD IONS NBIX BLUE

| Held by: VTI IWM VXF IWO XBI IBB VTWO SCHA IWC ONEQ

Index	RUT	P/E	-	EPS (ttm)	-3.77	Insider Own	43.26%	Shs Outstand	34.04M	Perf Week	1.94%
Market Cap	809.13M	Forward P/E	-	EPS next Y	-3.14	Insider Trans	0.00%	Shs Float	20.82M	Perf Month	-11.73%
Enterprise Value	633.19M	PEG	-	EPS next Q	-0.71	Inst Own	55.49%	Short Float	27.05%	Perf Quarter	23.18%
Income	-127.46M	P/S	-	EPS this Y	-42.52%	Inst Trans	1.18%	Short Ratio	17.33	Perf Half Y	-11.52%
Sales	0.00M	P/B	3.71	EPS next Y	13.96%	ROA	-46.92%	Short Interest	5.63M	Perf YTD	-17.23%
Book/sh	5.95	P/C	4.60	EPS next 5Y	9.66%	ROE	-49.00%	52W High	36.37 -39.37%	Perf Year	11.25%
Cash/sh	4.80	P/FCF	-	EPS past 3/5Y	-15.72% -	ROIC	-62.93%	52W Low	15.47 42.53%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.39% 5.58%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-69.17%	Oper. Margin	-	ATR (14)	1.17	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.34	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	50.39	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	14.34	EPS Q/Q	-263.73%	SMA20	0.26%	Beta	1.22	Target Price	39.40
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	1.24%	Rel Volume	0.97	Prev Close	22.72
Employees	52	LT Debt/Eq	0.00	Earnings	May 12 BMO	SMA200	-9.91%	Avg Volume	325.05K	Price	22.05
IPO	Jan 26, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-186.14% -	Trades		Volume	316,541	Change	-2.95%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Resumed	Goldman	Buy	$33
Mar-20-25	Initiated	B. Riley Securities	Buy	$37
Mar-10-25	Initiated	Guggenheim	Buy	$45
Jul-22-24	Initiated	Oppenheimer	Outperform	$35
Apr-30-24	Initiated	H.C. Wainwright	Buy	$25
Feb-20-24	Initiated	Jefferies	Buy	$35
Feb-20-24	Initiated	Goldman	Buy	$27
Feb-20-24	Initiated	Citigroup	Buy	$30

Jul-01-25 11:15PM	ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:05PM	ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jun-23-25 07:00AM	ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study (GlobeNewswire) -9.60%
Jun-20-25 04:05PM	ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC (GlobeNewswire)
May-12-25 08:00AM	ArriVent BioPharma Reports First Quarter 2025 Financial Results (GlobeNewswire)
08:00AM	Loading…
Apr-28-25 08:00AM	ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors (GlobeNewswire)
Mar-19-25 04:23PM	ArriVent BioPharma (AVBP): Among the Best Short Squeeze Stocks to Buy According to Analysts (Insider Monkey)
Mar-03-25 07:00AM	ArriVent BioPharma Reports Full Year 2024 Financial Results (GlobeNewswire) -6.69%
Jan-23-25 07:05AM	ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright (TipRanks)
Jan-22-25 05:00AM	Intellia makes progress on HAE study; 2 more China drug deals (BioPharma Dive) +5.22%
Jan-21-25 07:00PM	ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers (GlobeNewswire)
Nov-14-24 08:00AM	ArriVent BioPharma Reports Third Quarter 2024 Financial Results (GlobeNewswire) -11.86%
Oct-11-24 07:02PM	Octagon Capital Advisors LP Increases Stake in ArriVent BioPharma Inc (GuruFocus.com)
Sep-09-24 12:05PM	ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer (GlobeNewswire)
Aug-19-24 09:55AM	Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet (Zacks)
09:54PM	Loading…
Aug-14-24 09:54PM	AVBP Stock Earnings: ArriVent BioPharma Misses EPS for Q2 2024 (InvestorPlace)
04:01PM	ArriVent BioPharma Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-12-24 08:00AM	ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer (GlobeNewswire)
Jun-05-24 07:00AM	ArriVent Announces a Multi-Target ADC Collaboration with Alphamab (GlobeNewswire)
May-16-24 04:05PM	ArriVent Appoints John Hohneker, M.D., to its Board of Directors (GlobeNewswire)
May-08-24 12:54PM	AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	ArriVent BioPharma Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-22-24 04:05PM	ArriVent Appoints Kristine Peterson to its Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	ArriVent BioPharma Reports Full Year 2023 Financial Results (GlobeNewswire)
Feb-05-24 12:59PM	Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Paul Tudor Jones, Julian Robertson, Charles Edwards, Arcus Biosciences, Inc. (RCUS), Arrivent Biopharma Inc (AVBP), and More (Insider Monkey)
Jan-25-24 09:30PM	ArriVent Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company. It focuses on identifying, licensing and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company was founded Zheng Bin Yao and Stuart Lutzker on April 14, 2021 and is headquartered in Newtown Square, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LaChapelle Robin	Chief Operating Officer	Jul 11 '25	Option Exercise	2.28	11,153	25,429	135,736	Jul 15 07:00 AM
LaChapelle Robin	Chief Operating Officer	Sep 19 '24	Option Exercise	3.28	27,566	90,481	124,583	Sep 23 06:14 PM

Open in Screener

ACET

Adicet Bio Inc

Jul 18 • 04:00PM ET

0.7595

Dollar change -0.0305
Percentage change -3.86	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP FATE NTLA ALLO AGIO GILD BLUE EDIT IMTX SGMO

| Held by: VTI VXF FESM BTEC CHNA

Index	-	P/E	-	EPS (ttm)	-1.29	Insider Own	20.99%	Shs Outstand	82.71M	Perf Week	1.33%
Market Cap	62.82M	Forward P/E	-	EPS next Y	-0.89	Insider Trans	0.00%	Shs Float	65.35M	Perf Month	12.97%
Enterprise Value	-71.37M	PEG	-	EPS next Q	-0.30	Inst Own	49.04%	Short Float	5.07%	Perf Quarter	32.94%
Income	-117.32M	P/S	-	EPS this Y	24.19%	Inst Trans	-3.53%	Short Ratio	6.70	Perf Half Y	-18.32%
Sales	0.00M	P/B	0.39	EPS next Y	12.23%	ROA	-48.44%	Short Interest	3.32M	Perf YTD	-21.05%
Book/sh	1.95	P/C	0.42	EPS next 5Y	19.34%	ROE	-55.83%	52W High	1.70 -55.32%	Perf Year	-40.66%
Cash/sh	1.82	P/FCF	-	EPS past 3/5Y	12.69% 36.74%	ROIC	-67.15%	52W Low	0.45 69.87%	Perf 3Y	-95.67%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.26% 6.59%	Perf 5Y	-95.28%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	56.29%	Oper. Margin	-	ATR (14)	0.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.34	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.93	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	9.34	EPS Q/Q	12.56%	SMA20	10.39%	Beta	1.59	Target Price	6.00
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	8.71%	Rel Volume	0.54	Prev Close	0.79
Employees	152	LT Debt/Eq	0.08	Earnings	May 06 AMC	SMA200	-15.92%	Avg Volume	495.08K	Price	0.76
IPO	Jan 26, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.54% -	Trades		Volume	269,712	Change	-3.86%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-30-24	Resumed	Guggenheim	Buy	$7
Sep-11-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-27-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-27-23	Downgrade	Guggenheim	Buy → Neutral
Jun-01-23	Downgrade	JP Morgan	Overweight → Neutral	$20 → $6
Sep-21-22	Initiated	JP Morgan	Overweight	$23
Mar-31-22	Initiated	SMBC Nikko	Outperform	$28
Mar-08-22	Initiated	Truist	Buy	$30
Mar-04-22	Initiated	Jefferies	Buy	$27
May-18-21	Initiated	BTIG Research	Buy	$34
Apr-23-21	Initiated	H.C. Wainwright	Buy	$27
Apr-14-21	Initiated	Canaccord Genuity	Buy	$28
Apr-08-21	Initiated	Guggenheim	Buy	$22
Nov-04-20	Initiated	B. Riley Securities	Buy	$30
Oct-27-20	Initiated	JMP Securities	Mkt Outperform	$30
Oct-16-20	Initiated	Wedbush	Outperform	$25

Show Previous Ratings

May-21-25 04:00PM	Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference (Business Wire) -6.59%
May-09-25 12:00PM	Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know (Zacks) +27.49%
May-06-25 04:01PM	Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates (Business Wire) -9.44% -18.65%
Apr-30-25 04:47PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.41% -5.07%
07:00AM	Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference (Business Wire)
04:30PM	Loading…
Apr-28-25 04:30PM	Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting (Business Wire) +5.82%
Apr-17-25 07:00AM	Adicet Bio Appoints Michael Grissinger to the Board of Directors (Business Wire) -7.96%
Mar-31-25 05:12PM	Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.06%
07:00AM	Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference (Business Wire)
Mar-23-25 08:43AM	Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-06-25 04:01PM	Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress (Business Wire) -5.90%
Mar-03-25 07:00AM	Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting (Business Wire) -5.70%
Feb-27-25 08:36AM	Adicet Bio shares rise on FDA Fast Track Designation for ADI-001 (Investing.com)
07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc) (Business Wire)
Feb-05-25 07:10AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement (Business Wire) +9.79%
06:06PM	Loading…
Jan-31-25 06:06PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-29-25 07:00AM	Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference (Business Wire)
Jan-08-25 04:10PM	Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones (Business Wire)
Dec-31-24 04:48PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.81%
Dec-19-24 07:00AM	Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire)
Dec-18-24 07:00AM	Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer (Business Wire) -6.28%
Nov-29-24 04:44PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-18-24 04:00PM	Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire) +6.42%
07:00AM	Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases (Business Wire)
Nov-16-24 09:00AM	Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 (Business Wire)
Nov-06-24 04:00PM	Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Nov-05-24 07:00AM	Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 (Business Wire)
Nov-01-24 07:00AM	Adicet Bio to Participate in Upcoming Investor Conferences (Business Wire)
Oct-31-24 05:31PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.88%
Oct-17-24 07:27AM	Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials (TipRanks)
07:00AM	Loading…
Oct-16-24 07:00AM	Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome (Business Wire) +6.43%
Sep-30-24 05:08PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:30PM	Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference (Business Wire)
07:00AM	Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases (Business Wire)
Sep-19-24 07:00AM	ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue (Business Wire)
Aug-30-24 05:44PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-27-24 04:00PM	Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire) -7.84%
Aug-19-24 07:00AM	Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors (Business Wire)
Aug-13-24 07:00AM	Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Aug-01-24 04:00PM	Adicet Bio to Participate in Upcoming Investor Conferences (Business Wire)
Jul-31-24 05:25PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-25-24 01:24AM	Why Is Adicet Bio, Inc. (ACET) a Good One-Dollar Stock to Buy According to Hedge Funds? (Insider Monkey)
Jul-09-24 09:52AM	Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag (Zacks)
07:34AM	Adicet Bio's ADI-270 receives FDA Fast Track Designation for kidney cancer treatment (Pharmaceutical Business Review)
Jul-08-24 07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (Business Wire) +9.35%
Jun-28-24 05:00PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.70%
Jun-24-24 07:00AM	Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma (Business Wire) +9.49%
Jun-21-24 11:10AM	Is Adicet Bio, Inc. (NASDAQ:ACET) the Best Halal Stock ? (Insider Monkey)
10:53AM	7 Best Halal Stocks To Buy Now (Debt Free) (Insider Monkey)
Jun-10-24 07:22PM	Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 (InvestorPlace)
Jun-05-24 07:00AM	Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis (Business Wire) +5.88%
May-31-24 05:41PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-29-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference (Business Wire) -7.05%
May-14-24 09:54PM	ACET Stock Earnings: Adicet Bio Beats EPS for Q1 2024 (InvestorPlace) -7.64% +5.26%
04:01PM	Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
10:00AM	Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress (Business Wire)
May-07-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference (Business Wire)
Apr-30-24 05:10PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.29%
Apr-22-24 04:30PM	Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting (Business Wire)
Apr-08-24 07:00AM	Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference (Business Wire)
Apr-04-24 08:38AM	Why Adicet Bio (ACET) Stock Might be a Great Pick (Zacks)
Apr-01-24 09:40AM	Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-28-24 05:19PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-22-24 09:35AM	Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +7.35%
Mar-19-24 09:53PM	ACET Stock Earnings: Adicet Bio Meets EPS for Q4 2023 (InvestorPlace) +5.42%
04:10PM	Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Mar-15-24 09:40AM	Are Medical Stocks Lagging Adicet Bio (ACET) This Year? (Zacks)
Mar-11-24 07:00AM	Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (Business Wire)
Feb-29-24 07:46PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-28-24 09:40AM	Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-12-24 09:40AM	Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-05-24 04:01PM	Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (Business Wire)
Jan-31-24 04:39PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-30-24 12:51PM	Hedge Fund and Insider Trading News: Larry Robbins, Ray Dalio, Two Sigma Investments, Point72 Asset Management, Bluebell Capital Partners, Adicet Bio Inc (ACET), Netflix, Inc. (NFLX), and More (Insider Monkey)
Jan-25-24 04:01PM	Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares (Business Wire)
09:40AM	Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-22-24 11:43PM	Adicet Bio, Inc. Announces Pricing of Public Offering (Business Wire)
04:28PM	Adicet Bio, Inc. Announces Proposed Public Offering (Business Wire)
Jan-04-24 07:00AM	Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024 (Business Wire) +22.73%
Jan-03-24 04:01PM	Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook (Business Wire) -12.44%
Dec-29-23 04:50PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.62% +6.35%
Dec-10-23 12:00PM	Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting (Business Wire)
Nov-08-23 04:10PM	Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates (Business Wire) -6.02%
Nov-07-23 07:00AM	Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference (Business Wire) -8.04%
Nov-02-23 09:00AM	Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting (Business Wire) +13.85%
Oct-31-23 06:25PM	Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-04-23 12:00PM	Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference (Business Wire)
Sep-29-23 05:24PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-27-23 09:00AM	Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (Business Wire)
Aug-31-23 04:35PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.11%
Aug-12-23 08:16AM	Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely? (Simply Wall St.)
Aug-09-23 04:15PM	Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates (Business Wire) +11.90%
Aug-02-23 04:00PM	Adicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference (Business Wire)
Jul-31-23 04:50PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.24%
Jul-11-23 08:30AM	Adicet Announces Appointment of Katie Peng to the Board of Directors (Business Wire)
Jun-30-23 04:51PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.19% +12.35%
Jun-26-23 04:00PM	Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma (NHL) (Business Wire) -54.29%
Jun-01-23 07:00AM	Adicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference (Business Wire) -5.20%
May-31-23 04:53PM	Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-18-23 06:00AM	Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting (Business Wire)

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of "off-the-shelf" gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

CMPX

Compass Therapeutics Inc

MBX

MBX Biosciences Inc

KROS

Keros Therapeutics Inc

TERN

Terns Pharmaceuticals Inc

AVBP

ArriVent BioPharma Inc

ACET

Adicet Bio Inc

Upgrade your FINVIZ experience